Cargando…
MON-282 Treatment of Hyperprolactinemia with Ropinirole: An Open-Label Dose Escalation Study
Purpose Treatment of hyperprolactinemia and prolactinomas with ergoline dopamine agonists (DAs) can be complicated by intolerance and resistance. Ropinirole (ROP) is a low cost selective D2/D3 receptor non-ergot DA, approved for treatment of Parkinson’s disease and Restless Leg Syndrome, that has be...
Autores principales: | Tsang, Amanda, Dimino, Cara, Khandji, Alexander G, Panigrahi, Sunil Kumar, Page-Wilson, Gabrielle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209269/ http://dx.doi.org/10.1210/jendso/bvaa046.1524 |
Ejemplares similares
-
MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020) -
MON-258 Hyperprolactinemia: An Unusual Initial Presenting Manifestation of Multiple Sclerosis
por: Hodge, MaKenzie, et al.
Publicado: (2020) -
MON-427 An Interesting Case of Drug-Induced Hyperprolactinemia in a Patient Who Presented with Psychosis
por: Siddiqi, Asmat, et al.
Publicado: (2019) -
MON-275 Prolactin to Testosterone Ratio Predicts Pituitary Pathology in Hypogonadal Men with Mild Hyperprolactinemia
por: Naelitz, Bryan D, et al.
Publicado: (2020) -
Drug Induced Hyperprolactinemia
por: Venkatanarasu, Ashok, et al.
Publicado: (2021)